MEDANTAGlobal Health Limited
Healthcare · Medical Care Facilities · NSE · as of 2026-10-26 (delayed ~30 min in market hours)
Global Health Limited, together with its subsidiaries, provides healthcare services in India. The company offers treatments in the areas of digestive and hepatobiliary sciences, cardiac and cancer care, neurosciences, gastrosciences, orthopaedics, renal care, liver transplant, lung transplant, bone marrow transplant, chest surgery, gynaecology and gynaeoncology, paediatric care, obstetrics, emergency, ENT, head and neck surgery, internal medicine, respiratory and sleep medicine, peripheral vascular and endovascular sciences, endocrinology and diabetes, rheumatology and immunology, radiology and imaging, ophthalmology, critical care, dermatology, dentistry, and dietetics and nutrition, as well as plastic, aesthetic, and reconstructive surgery. It also provides second opinion, lab tests and diagnostics, homecare and elder care services, telemedicine and air ambulance services, and e-ICU services, and health plans checkup. In addition, the company is involved in trading of pharmacy and other medical consumables; and medical and healthcare education activities. The company operates a network of hospitals under the Medanta brand. Global Health Limited was incorporated in 2004 and is based in Gurugram, India.
Price & Volume
Loading chart…
Key Ratios
“—” means the figure isn't meaningful or isn't published for this company: ROE and Debt/Equity are undefined when shareholder equity is negative (check P/B — negative means negative equity), and DII/MF holding splits aren't provided by our current data source.
Active Pattern Signals
The picture
- • Revenue growth: 26.5% YoY
- • Debt/Equity: 0.30
- • Promoter holding: 66.4%
- • Golden cross setup: SMA50 above SMA200
- • Trend strength (ADX): 36
- • 6-month vs NIFTY: +12.4% relative
- • RSI Oversold Reversal signal (setup quality 58%)
Bull case
- • Revenue growth: 26.5% YoY
- • Debt/Equity: 0.30
- • Promoter holding: 66.4%
- • Golden cross setup: SMA50 above SMA200
Bear case
- • Profit growth: -0.2% YoY
- • Dividend yield: 0.04%
- • RSI: 31
- • MACD: bearish
Key risks
- • Momentum is fading versus the broader market
- • Profit growth: -0.2% YoY
- • Dividend yield: 0.04%
Algorithmic analysis for research only — not SEBI-registered investment advice.
Trade Plan
Stop = 20-day support with a 2.5×ATR risk cap (ATR ₹42.60). Levels recompute on every data refresh. Position sizing and execution are yours — this is analysis, not advice.